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Abstract
Objective: To study the molecular genetic and clinical features of cerebral cavernous malformations (CCM) in a cohort of
Spanish patients.
Methods: We analyzed the CCM1, CCM2, and CCM3 genes by MLPA and direct sequencing of exons and intronic boundaries
in 94 familial forms and 41 sporadic cases of CCM patients of Spanish extraction. When available, RNA studies were
performed seeking for alternative or cryptic splicing.
Results: A total of 26 pathogenic mutations, 22 of which predict truncated proteins, were identified in 29 familial forms and
in three sporadic cases. The repertoire includes six novel non-sense and frameshift mutations in CCM1 and CCM3. We also
found four missense mutations, one of them located at the third NPXY motif of CCM1 and another one that leads to cryptic
splicing of CCM1 exon 6. We found four genomic deletions with the loss of the whole CCM2 gene in one patient and a
partial loss of CCM1and CCM2 genes in three other patients. Four families had mutations in CCM3. The results include a high
frequency of intronic variants, although most of them localize out of consensus splicing sequences. The main symptoms
associated to clinical debut consisted of cerebral haemorrhage, migraines and epileptic seizures. The rare co-occurrence of
CCM with Noonan and Chiari syndromes and delayed menarche is reported.
Conclusions: Analysis of CCM genes by sequencing and MLPA has detected mutations in almost 35% of a Spanish cohort
(36% of familial cases and 10% of sporadic patients). The results include 13 new mutations of CCM genes and the main
clinical symptoms that deserves consideration in molecular diagnosis and genetic counselling of cerebral cavernous
malformations.
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Introduction
Cerebral Cavernous Malformations (CCMs; OMIM 116860)
are enlarged vascular cavities without intervening brain paren-
chyma with an estimated prevalence in the general population
close to 0.1–0.5 percent. Single or multiple malformations may
develop, which can lead to cerebral haemorrhage (30–40%),
seizures (40–70%), headache (10–30%) and focal neurological
symptoms (35–50%). The onset age is variable with higher
incidence between 10 and 40 years. CCM may occur sporadically
or with an autosomal dominant inheritance pattern with variable
expression and incomplete penetrance. Almost 25% of CCM
carriers remain symptom-free throughout their lives.
Genes responsible for CCM were mapped [1] and located on
7q21.2 (CCM1, KRIT1) [2,3], 7p13 (CCM2, MGC4607) [4] and
3q26.1 (CCM3, PDCD10) [5]. Close to 150 different mutations
have been described in CCM1 and almost all of them lead to
premature stop codons that predict truncated proteins [6,7].
Approximately 40 different mutations have been reported in the
CCM2 gene [4]. The encoded protein, malcavernin, contains a
phosphotyrosine binding (PTB) domain, similar to the Krit1
binding partner ICAP1a. Krit1 interacts with Icap1a and
malcavernin via their respective PTB domains [8]. Malcaverin
has been described to interact with TrkA via its PTB domain to
mediate TrkA-induced death in diverse cell types by a C-terminal
‘‘Karet’’ domain [9]. Finally, close to 15 different mutations have
been described in the CCM3 gene [5]. Recent findings describe the
core complex formed by the association of the three proteins
coded by CCM genes and their role in cytoskeletal remodelling,
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regulation of cell matrix adhesion and cell-cell junction homeo-
stasis [10].
We have previously reported CCM mutations in CCM1 and
CCM2 in patients of Spanish and Portuguese extraction. Here, we
further studied CCM1, CCM2 and CCM3 in consecutive cases of
Spanish patients including 94 CCM nuclear families and 41
sporadic cases. We report the identification of 13 novel mutations
in the CCM genes, including the activation of a cryptic splicing
signal. At the clinical level, we describe the main clinical symptoms
of patients together with the rare coincidence of CCM with Chiari
and Noonan syndromes and delayed menarche.
Methods
Patients
We recruited 94 consecutive families and 41 sporadic forms,
which comprise 254 patients with clinical symptoms and gradient-
echo MRI of CCM. Clinical assessment of patients included
information on cerebral haemorrhage, epileptic seizures, headache
and other neurological symptoms. The patients were classified as
having hereditary or sporadic CCM on the basis of MRI and
familial characteristics. Patients with at least one affected relativeFigure 1. Sequencing of exon 5 (reverse strand, CCM1) of
CV126 index patient showing mutation c.618_619delinsG.
doi:10.1371/journal.pone.0086286.g001
Figure 2. Quantitative MLPA analysis of (a) P130 and (b) P131 probemix (MRC Holland). Black columns represent CV146 index patient and
grey columns represent a healthy control. The deletion of exons 12 to 16 of CCM1 is shown.
doi:10.1371/journal.pone.0086286.g002
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and/or multiple cavernous malformations in MRI were classified
as having hereditary CCM. A written consent was obtained from
the patients and their relatives included in this study. The study
conformed to the tenets of the declaration of Helsinki and was
approved by the ‘‘Committee of Ethics and Clinical Investigation’’
from Hospital Universitario Virgen Macarena.
Molecular genetic analysis
Genomic DNA was extracted from peripheral blood using a
salting-out standard procedure. The initial mutation search was
performed by MLPA, using the SALSA P130 and P131 kits (MRC
Holland) to detect genomic deletions in the CCM genes. Data
analysis of MLPA was carried out with Coffalyser.NET Software
(MRC Holland). If no deletions were found, coding and flanking
intronic sequences were amplified with previously described
primers for CCM1 [2,3] and CCM2 [11]. Since CCM1 has several
variants, which differ in 59UTR exons, the first coding exon was
considered exon 1. We screened CCM3 exons with a set of 7 pairs
of primers (sequence of the primers available upon request).
Sequencing of both the sense and antisense strands, extending 30–
90 bases into the introns, was performed in a 3130 Genetic
Analyzer (Applied Biosystems). When a non-sense mutation was
identified we did not sequence the rest of genes. When a missense
mutation was detected, we further sequenced the entire CCM1,
CCM2 and CCM3 coding exons. When available, we performed
blood RNA studies to evaluate alternative or cryptic splicing.
Polyphen and SIFT prediction software were used to analyze
missense mutations. Mutations were confirmed in an independent
PCR amplification product either by sequencing of both forward
and reverse strands or by restriction analysis. The mutations
herein described were tested in approximately 200 chromosomes
from healthy donors. In the case of gross deletions, we tried to
delimit the breakpoints by reiterative PCR amplifications using
primers extending up to approximately 2Kb 59 and 39 of the
MLPA probes. In order to make data publicly available, mutations
were submitted to the ‘‘Angioma Alliance’’ database (www.
angiomaalliance.org, Durham, NC).
Results
CCM1
Sequencing of coding exons and intronic boundaries of CCM1
identified 20 mutations, eight of which were novel (table 1). A C-
to-T transition at nucleotide 1114 resulted in nonsense mutation
Q372X. Three frameshift mutations were identified: i) a nucleo-
tide deletion in exon 6 (c.801delA, p.Lys267AsnfsX8); ii) an 11 bp
deletion between positions 1314 to 1325 that predicts a truncated
protein of 474 aminoacids; and iii) a small indel in exon 5 resulting
in the deletion of CA at nucleotide position 618, and the insertion
of one G, c.618_619delinsG (figure 1). Two gross genomic
deletions were detected by MLPA in two unrelated patients, which
encompass the three 59non-coding exons and exons 12–16
(figure 2). Finally, we detected three nucleotide transitions at
positions 691, 842 and 1775 that lead to the missense mutations
p.N231D, p.D281G and p.S592T. None of these mutations had
been previously reported (table 1). Known polymorphisms
rs2027950 and rs11542682 were also detected.
Table 1. Mutations identified within the CCM1 gene (NM_194455.1).
Pedigree
No. of affected
individuals Age at MRI Exon/Intronc
Nucleotide
change Mutation consequence
Predicted amino
acid change Condition
CV171 6 NC 1–3 59UTR Gross deletion NA [12] Pathogenic
CV126 4 21–59 5 c.618_619delinsGa Frameshift p.His207ValfsX6 Pathogenic
CV122b 1 5 c.691A.Ga Missense p.N231D Possibly pathogenic
CV148 6 7–42 6 c.801delAa Frameshift p.Lys267AsnfsX8 Pathogenic
CV150b 1 69 6 c.842A.Ga Missense.altered splice site p.Asp281GlyfsX5 Pathogenic
CV118 2 6, 40 7 c.880C.T Nonsense p.R294X [12] Pathogenic
CVs 133, 163 3 7 c.902C.G Nonsense p.S301X [3] Pathogenic
CV59 2 40,39 7 c.923T.A Missense p.L308H [14] Unknown
CV87 7 9–61 7 c.968_971dupCACC Frameshift p.Ile325ThrfsX11 [14] Pathogenic
CV160 2 8 c.1114C.Ta Nonsense p.Q372X Pathogenic
CV129 2 IVS9 c.1255-4delGTA Altered splice site NA [21] Pathogenic
CV116 1 25 10 c.1314_1325dela Frameshift p.Gly439HisfsX36 Pathogenic
CV79 1 28 10 c.1360_1363delTCTC Frameshift p.Ser454LysfsX39 [6,14] Pathogenic
CV36 1 18 10 c.1362_1363delTC Frameshift p.Gln455ArgfsX23 [14] Pathogenic
CV136b 1 8 12 c.1579G.A Missense p.A527T [6] Pathogenic
CV105, 147 2 20, 43 IVS12 c.1730+5G.A Altered splice site NA [12] Pathogenic
CV86 3 17–41 IVS12 c.1730+4delAGTA Altered splice site NA [6,14] Pathogenic
CV166 1 NA 13 c.1775G.Ca Missense p.S592T Unknown
CV10 5 4–80 14 c.1904InsA Nonsense p.Y635X [14] Pathogenic
CV146 2 20 12–16 Exons 12–16 dela Genomic deletion NA Pathogenic
aNew mutation non-previously reported.
bSporadic patient.
cExon count begins with exon 1 as the first coding exon for CCM1.
NA: not avialable. NC: 59 untranslated exons.
doi:10.1371/journal.pone.0086286.t001
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Figure 3. Mutation analysis in the CV150 patient. (a) Sequencing of exon 6 (CCM1 gene), which shows the A.G transition at position 842. (b)
cDNA sequencing of exons 5 to 8 of a healthy subject and (c) the CV150 patient. A new 59 splice site is created at the mutation site. The new splicing
alters the open reading frame of exon 7 and generates a premature stop codon (p.Asp281GlyfsX5). (d) Diagram showing the cryptic splicing of exon 6
to exon 7 in the patient. Codons are shown in consecutive blue and black colour and premature stop codon in red colour. The arrow shows the novel
donor splice site.
doi:10.1371/journal.pone.0086286.g003
Table 2. Mutations identified within the CCM2 gene (NM_031443.3).
Pedigree
No. of affected
individuals Age at MRI Exon/Intron Nucleotide change
Mutation
consequence
Predicted amino
acid change Condition
CV77 1 50 All delCCM2 Gross deletion NA [15] Pathogenic
CV128 5 39–72 1 59UTR-exon1del Gross deletion NA [12,15] Pathogenic
CV140 1 55 2 c.55C.T Nonsense p.R19X [22] Pathogenic
CV100 1 41 2 c.169_172delAGAC Frameshift p.Arg57CysfsX1 [14] Pathogenic
CV145 2 3 c.222G.Aa Transition None Non pathogenic
CVb 15 22–78 5 c.554_567del Frameshift p.Ala186GlyfsX44 [14] Pathogenic
CV114 1 6 c.713C.Aa Missense p.S238Y Possibly pathogenic
aNew mutation non-previously reported.
bThe c.554_567del is a redundant mutation that was detected in 11 unrelated Spanish families [14].
NA: not available.
doi:10.1371/journal.pone.0086286.t002
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We analysed two missense mutations at the cDNA level.
Mutation c.842A.G in exon 6 of CCM1 predicts the aminoacid
change D281G. Nevertheless, sequencing of the patient’s cDNA
revealed that mutation D281G resulted in an altered donor site at
the point of mutation (figure 3), which causes a cryptic splicing,
alters the open reading frame and predicts a truncated protein of
286 aminoacids (p.Asp281GlyfsX5). On the other hand, missense
mutation p.S592T did not modify the wild-type splicing.
CCM2
The CCM2 gene was studied in non-CCM1 patients by MLPA
and sequencing. MLPA detected two gross genomic deletions.
One of them included the whole genomic sequence covered by the
MLPA probes, while the second deletion affected the 59UTR and
the first exon (table 2). The size of these two deletions could not be
accurately determined by successive PCRs up to 2 Kb around the
MLPA probes. Sequencing of CCM2 detected three previously
described nonsense and frameshift mutations, c.55C.T (p.R19X),
c.169_172delAGAC and c.554_567del (table 2). Two non-
previously described point mutations were also identified: i) the
nucleotide transversion 713C.A that leads to missense mutation
p.S238Y; and ii) the silent G.A transition at position 222.
Polymorphisms rs2107732 (exon 2), rs2304689 (intron 3),
rs11552377 (exon 4), rs2289367 (exon 8) and rs190686229 (intron
9) were found in 21, 3, 12, 10 and 2 families, respectively.
CCM3
We studied CCM3 by MLPA and sequencing in CCM1- and
CCM2-negative patients. MLPA failed to detect deletions in the
coding sequence in the patients. Sequencing of the CCM3 gene
uncovered three novel point mutations: i) a G-to-C transition at
the splicing donor site of intron 7; ii) deletion c.211delA that
predicts a truncated protein of 88 aminoacids; and iii) an A
insertion at nucleotide 538 causing a frameshift followed by a stop
codon at residue 183 (table 3). We also detected the intronic
variant c.268+53C.T (intron 5).
Clinical outcomes
The main clinical symptoms at debut of the disease were
headaches (36%), epileptic seizures (25%), instability and dizziness
(18%), migraines (12%), hemorrhage (5%), and myoclonic seizures
(1%). Three cases were discovered after MRI in patients with
clinical diagnosis of: i) Noonan syndrome associated to Arnold-
Chiari malformation; ii) a nine year old girl with premature
menarche; and iii) a patient with clinical diagnosis of possible
metastasis secondary to non-cerebral cancer (table 4).
Discussion
Mutations in the CCM1, CCM2 and CCM3 genes account for
65%, 19% and 16% of CCM cases, respectively [12]. Here we
describe the genetic study of a group of 94 and 41 cases of familial
and sporadic CCM, comprising a total of 254 patients. We report
the identification of 31 mutations in the CCM genes, 13 of which
have not been previously described. The identified mutations
include nonsense, frameshift, missense and splice variants.
Interestingly, RNA studies have revealed the use of a cryptic
splice site leading to a frameshift by one of the missense mutant
alleles.
The prevalence of mutations in this study, 36% and 10% for
familial and sporadic forms, respectively, is relatively lower than
previous reports [12,13]. Among the 31 mutations identified in this
work, 13 of them are novel. It is worth mentioning that among the
nearly 200 different mutations that have been described in CCM
patients thus far, there is a very low degree of recurrence among
different families. Two exceptions are the c.1363C.T transition
in the CCM1 gene, which is highly prevalent in the Hispanic-
Mexican population [3] and a 14 bp-deletion in CCM2 previously
detected in patients of Spanish and Portuguese descent [14].
In this work, we identified a total of 31 mutations including 5
nonsense, 10 frameshift and 6 missense mutations and four exonic
deletions. Using MLPA, we were able to detect four genomic
deletions in four unrelated families. One of the patients carries a
deletion encompassing the whole CCM2 gene, as previously
reported [15]. The deletion of three non-coding exons of CCM1in
patient CV171 leads to loss of the transcription initiation site and
therefore absence of the full-length transcript should be expected.
The deletion of CCM1 exons 12–16 was identified in a single
nuclear family. Finally, we identified one deletion that encom-
passes the ATG start codon of CCM2 and that expands into the
59UTR. The breakpoints of these deletions could not be accurately
determined using a long-range PCR apporach. Therefore, they
were defined relative to the position of the MLPA-DNA probes.
The nature of CCM1 mutations has been reported to be highly
stereotyped leading to premature termination codon through
different mechanisms, including missense mutations that activate
cryptic splice sites [6,7,12]. In this line, we were able to analyze an
RNA sample of two patients with missense mutations p.D281G
and p.S592T in the CCM1 gene. Mutation p.D281G generates a
novel donor site leading to cryptic splicing (figure 3), which alters
the open reading frame and predicts a truncated protein of 286
aminoacids (p.Asp281GlyfsX5). On the other hand, mutation
p.S592T in CCM1 showed both alleles at cDNA level and no
cryptic splicing event was found. The mutated residue is located in
the F2 FERM domain of Krit1. At the protein level serine 592 is
conserved among different species and is predicted to be damaging
Table 3. Mutations identified within the CCM3 gene (NM_007217).
Pedigree
No. of affected
individuals Age at MRI Exon/Intron
Nucleotide
change
Mutation
consequence
Predicted amino acid
change Condition
CV139 1 5 c.211delAa Frameshift p.Ser71AlafsX18 Pathogenic
CV127 1 IVS6 c.395+1G.Ca Altered splice site NA Pathogenic
CV164b 1 IVS7 c.474+5G.A Altered splice site p.Asp133HisfsX10 [17] Pathogenic
CV125 2 8 c.538dupAa Frameshift p.Tyr180AsnfsX3 Pathogenic
aNew mutation non-previously reported.
bSporadic patient.
NA: not available.
doi:10.1371/journal.pone.0086286.t003
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according Polyphen (score: 0.709) and tolerated by SIFT (score:
0.08). Therefore, the pathogenicity of the p.S592T mutation
remains unclear. Although cDNA analysis of the p.N231D
mutation in CCM1 could not be carried out, Polyphen (score:
0.982) and SIFT (score: 0) analysis point out to a pathogenic
mutation. Finally, among the polymorphisms found in the CCM1
gene, a silent substitution at nt 1980 (rs11542682) was detected in a
heterozygous state in 12% in our patients, a slightly lower frequency
than previously reported [6]. The frequency of the intronic transition
c.989+63C.G (rs2027950) was similar to other populations.
The analysis of CCM2 in our cohort revealed two new
mutations. RNA study of CV145 index patient, carrier of the
silent transition 222G.A, showed both mutant and wild type
alleles and did not reveal aberrant splicing of CCM2. Therefore,
the transition should be considered as avariant without pathogenic
significance [12]. While RNA was not available to study the
c.713C.A (p.S238Y) mutation, bioinformatic analysis suggests
that this mutation would be pathogenic (Polyphen score: 0.993;
SIFT score: 0.03). Moreover, p.S238 is a phosphorylation site [16]
and the mutation could affect to CCM2 function. The frequency of
polymorphisms c.157G.A (rs2107732), c.205-36A.G
(rs2304689), c.358G.A (rs11552377), c.915G.A (rs2289367)
and c.1054+12C.T (rs190686229) were similar to other popula-
tions and to the 1000 genomes project database (http://www.
1000genomes.org/ensembl-browser; accessed 10 Apr 2013). Some
of these polymorphisms had been associated with a significant
increase in the risk for CCM and a predisposition to a higher
occurrence of a ‘potentially disabling’ symptomatology rather than
to a ‘possibly life-threatening’ symptomatology [13]. In addition
we studied some previously described polymorphisms which are
very frequent in our patients’ cohort: c.157G.A, c.358G.A and
c.915G.A. None of them showed an altered cDNA sequence and
no evidence of alternative splicing was found.
The mutation responsible for the disease remains undiscovered
in 65% of familial forms in this work. Several explanations have
been proposed for this apparent low detection: i) the existence of
mosaicism or genomic deletions non-detected by the exon-by-exon
sequencing approach [5]; ii) the existence of an additional fourth
CCM locus close to CCM3 [17]; and iii) deep intronic mutations
that could activate alternative or cryptic sites [18]. In both,
patients and controls, several aberrant splicing events in CCM1
gene have been described in peripheral blood mononuclear cells
[19]. We aimed to analyze this possibility in our cohort of patients
and controls. Preliminary results indicated the lack of association
of the detected isoforms with the disease (data not shown).
Regarding the clinical symptoms in the patients’ cohort, we
studied four unrelated families with radiological images of
developmental venous anomalies (DVAs) and CCMs. None of
them carried a pathogenic mutation in the CCM genes. Moreover,
the father and the daughter of CV146 carry of a gross deletion in
CCM1, whereas the son, who has radiological images of DVA, did
not carry the deletion. In the light of a recent report [20], our
findings support a separate pathogenic mechanism for DVAs and
CCMs. Besides the classical clinical features of CCM, the main
findings in the patients studied here are the coincidence of
cavernomas with Chiari and Noonan syndromes and with delayed
menarche. It is worth to point out that these casual findings do not
imply a pathogenic association between cavernomas and the
above-described syndromes.
We can conclude that the analysis of CCM genes by sequencing
and MLPA has detected mutations in almost 35% of a Spanish
cohort (36% of familial cases and 10% of sporadic patients). The
results comprise 13 non-previously described mutations, including
the aminoacid change p.D281G that leads to cryptic splicing and
thus, a frameshift mutation. Moreover, the co-occurrence of
additional syndromes together with CCM deserves consideration
in molecular diagnosis and genetic counseling of cerebral
cavernous malformations.
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